MedTrace Logo

Treating Early Stage Diabetic Retinopathy

NCT05132660 · Status: ENROLLING_BY_INVITATION · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 244

Last updated 2026-04-07

No results posted yet for this study

Summary

To determine if levodopa will slow the appearance of blood vessel changes in the eyes of patients with diabetes. Treatment will be started in patients with diabetes show delays in the electrical activity of the retina when measured non-invasively with a electroretinogram.

Conditions

Interventions

DRUG

Sinemet CR

25 mg carbidopa/100 mg levodopa

DRUG

placebo

Placebo pill of similar size/shape

Sponsors & Collaborators

  • Emory University

    collaborator OTHER

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Machelle T. Pardue, PhD · Atlanta VA Medical and Rehab Center, Decatur, GA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2027-12-31
Completion
2028-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05132660 on ClinicalTrials.gov